Company / Operating Cash Flow
Amneal Pharmaceuticals, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$340.0M
FY2025
5-year range
$1.7M / $340.0M
FY2021-FY2025
Trend
+15.2%
vs FY2024
Sector context
#33 of 216
Health Care
What the data says
Amneal Pharmaceuticals, Inc.'s operating cash flow of $340M is higher than 85% of companies in the Health Care sector (FY2025). Operating Cash Flow has increased for 4 consecutive years, from $2M in FY2021 to $340M in FY2025.
Based on SEC 10-K filings.
$340M in FY2025 with a 5-year CAGR of +6.3%. Top quartile in the Health Care sector.
Improved from $242M to $340M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +73.5%
- 5-Year CAGR
- +6.3%
- 10-Year CAGR
- -
Sector benchmark
-48.4% below sector average
Key checks
Key Insights
- Amneal Pharmaceuticals, Inc.'s operating cash flow has grown for 4 consecutive years.
- 5-year CAGR of +6.3%, indicating consistent growth.
- In FY2025, operating cash flow increased 15.2% year-over-year.
- Ranks #33 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $340.0M | +15.2% |
| FY2024 | $295.1M | +22.0% |
| FY2023 | $241.8M | +271.5% |
| FY2022 | $65.1M | +3718.2% |
| FY2021 | $1.7M | -99.3% |
| FY2020 | $250.2M | +6.9% |
| FY2019 | $234.2M | +103.5% |
| FY2018 | $115.1M | -50.9% |
| FY2017 | $234.2M | +103.5% |
| FY2016 | $115.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026